Overview
Adstiladrin is approved by the U.S. Food and Drug Administration (FDA) to treat adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). This includes…

Overview
Anktiva is approved by the U.S. Food and Drug Administration (FDA) along with Bacillus Calmette-Guérin (BCG) to treat adults with a type of bladder cancer called BCG-unresponsive nonmuscle invasive bladder cancer…

Overview
Balversa is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) with specific fibroblast growth…

Overview
Bavencio is approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) that has not progressed with…

Overview
Imfinzi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with muscle-invasive bladder cancer (MIBC) in combination with chemotherapy prior to surgery (neoadjuvant), followed…

Overview
Inlexzo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ…

Overview

Keytruda is approved by the U.S. Food and Drug Administration (FDA) to treat certain types of bladder cancer. It is prescribed to treat advanced or metastatic (spreading) urothelial cancer, nonmuscle invasive…

Overview
Keytruda Qlex is approved by the U.S. Food and Drug Administration (FDA) to treat several forms of bladder cancer, which is the most common type of urothelial cancer. It is approved in combination with enfortumab…

Overview
Opdivo is approved by the U.S. Food and Drug Administration (FDA) to treat certain types of bladder cancer, called urothelial carcinoma. It can be used after surgery to lower the risk of the cancer coming back in…

Overview
Padcev is approved by the U.S. Food and Drug Administration (FDA) to treat several forms of bladder cancer. It is approved in combination with pembrolizumab (Keytruda) or with pembrolizumab and berahyaluronidase…

Overview
Tepadina is approved by the U.S. Food and Drug Administration (FDA) for the treatment of superficial papillary carcinoma of the urinary bladder, a form of bladder cancer. This treatment is typically used for…

Overview
Tice BCG is approved by the U.S. Food and Drug Administration (FDA) to treat and prevent carcinoma in situ (CIS, a type of bladder cancer that stays on the bladder lining). It is also used to prevent the…

Overview
Valstar is approved by the U.S. Food and Drug Administration (FDA) to treat carcinoma in situ (CIS), a type of bladder cancer that has not spread beyond the bladder lining, in people who did not respond to…

Overview

Zusduri is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (NMIBC). It is indicated for people…